Drug resistance-associated mutations in antiretroviral treatment-naïve and -experienced patients in Kuwait
Abstract
The identification of human immunodeficiency virus (HIV) mutations leading to drug resistance enables patient-specific adaptation of the treatment regimen and predicts the risk of transmission of drug-resistant HIV. In this study, we report for the first time the prevalence in Kuwait of non-polymorphic resistance-associated mutations (RAMs) in patients under first-line antiretroviral therapy. Viral RNA was extracted from plasma samples of 64 treatment-naïve (untreated) and 64 treatment-experienced patients. The HIV-1 load was determined by real-time RT-PCR. The protease- and reverse transcriptase-encoding regions were analyzed by subtyping, and for drug resistance. The HIV-1 load at sampling in treatment-naïve patients ranged from 1.61 x 104 to 1.91 x 106 copies/ml, whereas that in treatment-experienced patients ranged from bitors (PIs) and NNRTIs. These results necessitate efforts to be made for reducing emergence of resistance-associated mutations in treated patients, and highlight the need for continuous monitoring of drug resistance patterns in Kuwait.
Keywords: HIV-1; genotyping; mutations; drug resistance; surveillance; Kuwait..
Similar articles
Chehadeh W, Albaksami O, Altawalah H, Ahmad S, Madi N, John SE, Abraham PS, Al-Nakib W.J Med Virol. 2015 Sep;87(9):1521-6. doi: 10.1002/jmv.24212. Epub 2015 May 14.PMID: 25976289
Drug Resistance-Associated Mutations in Antiretroviral Treatment-Experienced Patients in Kuwait.
Chehadeh W, Albaksami O, John SE, Al-Nakib W.Med Princ Pract. 2018;27(2):152-157. doi: 10.1159/000488108. Epub 2018 Mar 5.PMID: 29506011 Free PMC article.
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K.Verh K Acad Geneeskd Belg. 2001;63(5):447-73.PMID: 11813503 Review.
Tee KK, Kamarulzaman A, Ng KP.Med Microbiol Immunol. 2006 Jun;195(2):107-12. doi: 10.1007/s00430-005-0010-x. Epub 2006 Jan 11.PMID: 16404607
Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, Owiti P, Opollo V, Etard JF, Mukui I, Kim AA, Zeh C.PLoS One. 2017 Feb 8;12(2):e0171124. doi: 10.1371/journal.pone.0171124. eCollection 2017.PMID: 28178281 Free PMC article.
Cited by
Garshasbi S, Marjani A, Alipour A, Khanaliha K, Esghaei M, Fakhim A, Bokharaei-Salim F.Iran J Microbiol. 2021 Dec;13(6):878-886. doi: 10.18502/ijm.v13i6.8094.PMID: 35222867 Free PMC article.
Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
Chehadeh W, Albaksami O, Al-Shammari S.Antivir Chem Chemother. 2020 Jan-Dec;28:2040206620927908. doi: 10.1177/2040206620927908.PMID: 32434393 Free PMC article.